Welcome Guest, Give the Gift of Health to Your Loved Ones
Baliarsingh et al investigated the therapeutic impacts of tocotrienols on serum and lipoprotein lipid levels in type 2 diabetic patients. A randomized, double blind, placebo-controlled design involving 19 type 2 diabetic subjects with hyperlipidemia was used. After 60 days of tocotrienol rich fraction(TRF) treatment, subjects showed an average decline of 23, 30, and 42% in serum total lipids, TC, and LDL-C, respectively. The goal in type 2 diabetics is to reduce LDL-C levels < or = 100mg/dl. In the present investigation tocotrienols mediated a reduction of LDL-C from an average of 179 mg/dl to 104 mg/dl
These findings suggest that daily intake of dietary TRF by individuals with type 2 diabetes will be useful in the prevention and treatment of hyperlipidemia and atherogenesis. Baliarsingh S, Beg ZH ,Ahmad J. The therapeutic effects of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis 2005 Oct; 182(2):367-364.
TRF lowers lipid peroxidation, which in turn reduces intimal thickening and preserves the internal elastic lamina in artery walls. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956867/ Tocotrienols’ cardioprotective effects are mediated through their antioxidant mechanisms and their ability to suppress inflammation, and inhibit HMG-CoA reductase, a rate-limiting enzyme in cholesterol biosynthesis. Probiotics and prebiotics also influence LDL-C levels.